Skip to main content

dacomitinib

Generic: DACOMITINIB·Brand: VIZIMPRO, Vizimpro

dacomitinib: sourced relationships with 1 company · 1 clinical trial tracked · 1 FDA decision.

dacomitinib evidence translation

What we can confirm

1 FDA record · 1 tracked trial

What it means

Source-backed records connect dacomitinib to PFE; that link alone does not prove the drug works.

What to watch

Watch active trials and any change in FDA or trial status.
BioSniper AIPage evidence connected

Prepared research question

How could dacomitinib → PFE affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 0 study sponsors

Related indications

Cancer

Study sponsors

No additional listed-company sponsor is linked.

Dated Pipeline Records (2)
CompanyDated record stage
PFIZER INC (PFE)
Reported 2018-09-27 · Current development: unknownSource
Approved
PFIZER INC (PFE)
Reported 2018-09-27 · Current development: unknownSource
Approved
Clinical Trial Registry Records (1)

A Dutch National Study on Behalf of the CPCT to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to Determine the Potential Efficacy in Treatment of Advanced Cancers With a Known Molecular Profile

NCT02925234Registry updated 2024-01-24·Phase 2
Recruiting

Primary endpoint: Percentage of patients that are treated based on their molecular tumor profile

Interventionalopen1,550 targetStarted 2016-08Completion 2027-1236 sites · NetherlandsThe Netherlands Cancer Institute
FDA Decisions1 records
Approval1 INDICATIONS AND USAGE VIZIMPRO is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test [see Dosage and Administration (2.1) ] . VIZIMPRO is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test. ( 1 )(PFE)FDA ↗
NDA211288Type 1 - New Molecular EntityOrphan DrugPriorityOralTablet

Frequently asked questions

Which companies have sourced relationships with dacomitinib?

dacomitinib has dated SEC/FDA relationship records for PFIZER INC.

How many clinical trials involve dacomitinib?

BioSniper tracks 1 clinical trial involving dacomitinib.

What is dacomitinib's latest FDA decision?

The most recent tracked FDA decision for dacomitinib is Approval for 1 INDICATIONS AND USAGE VIZIMPRO is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test [see Dosage and Administration (2.1) ] . VIZIMPRO is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test. ( 1 ), dated September 27, 2018.